Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients

Nephron - Clinical Practice

Volumn 99, Issue 3, 2005, Pages

  Driss, Fathi ^a   Vrtovsnik, François ^a   Katsahian, Sandrine ^a   Michel, Catherine ^a   Baron, Gabriel ^a   Kolta, Amir ^a   Sedrati, Nadia ^a   Mentré, France ^a   Mignon, Françoise ^a   Cabantchik, Ioav ^b   Grandchamp, Bernard ^a,c  

^a BICHAT HOSPITAL   (France)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c INSERM   (France)

Author keywords

Hemodialysis; Iron, non transferrin bound; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; ERYTHROPOIETIN; FERRITIN; FERROUS FUMARATE; FERROUS SULFATE; IRON; IRON POLYMALTOSE; ISOPROSTANE DERIVATIVE; LIPID HYDROPEROXIDE; MALTOFER; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 20144388440     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083208     Document Type: Article

References (13)

1. Sunder-Plassmann G, Horl WH: Novel aspects of erythropoietin response in renal failure patients. Nephrol Dial Transplant 2001;16(suppl 5):40-44.
2. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, Marx JJ: Non-transferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32(suppl 1):36-41.
3. Breuer W, Hershko C, Cabantchik ZI: The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000;23:185-192.
4. Marx JJ, Hider RC: Iron: An essential but potentially harmful nutrient. Eur J Clin Invest 2002:32(suppl 1):1-2.
5. Kletzmayr J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(suppl 2):25-29.
6. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-340.
7. Esposito BP, Breuer W, Slotki I, Cabantchik ZI: Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin-bound iron in dialysis patients. Eur J Clin Invest 2002;32(suppl 1):42-49.
8. Eskelinen S, Haikonen M, Raisanen S: Ferene-S as the chromogen for serum iron determinations. Scand J Clin Lab Invest 1983;43:453-455.
9. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI: Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 2001;97:792-798.
10. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ: A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-9387.
11. Altaye M, Donner A, Klar N: Inference procedures for assessing interobserver agreement among multiple raters. Biometrics 2001;57:584-588.
12. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.
13. Salahudeen AK, Oliver B, Bower JD, Roberts LJ: Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001;60:1525-1531.